- Home
- VNRX vs VRCA Comparison
VNRX vs VRCA Comparison
Compare VNRX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNRX | VRCA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 32.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | VNRX | VRCA |
|---|---|---|
| Price | $0.25 | $8.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 2.2M | 211.3K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,472,007.00 | ★ $30,829,000.00 |
| Revenue This Year | $55.98 | $373.20 |
| Revenue Next Year | $420.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.48 | ★ 234.73 |
| 52 Week Low | $0.22 | $3.28 |
| 52 Week High | $0.94 | $9.82 |
Technical Indicators
Market Signals| Indicator | VNRX | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 62.28 |
| Support Level | $0.22 | $7.60 |
| Resistance Level | $0.26 | $9.02 |
| Average True Range (ATR) | 0.02 | 0.84 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 42.29 | 72.08 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.